EMA/PE/0000223490 - paediatric investigation plan

Eptinezumab

Key facts

• Invented name:
  Vyepti
• Active substance:
  Eptinezumab
• Therapeutic area:
  • Surgical and medical procedures
  • Neurology
• Decision number:
  EMA/PE/0000223490
• PIP number:
  EMA/PE/0000223490
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Prevention of migraine headaches
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  28/01/2025
• Compliance check done:
  No

Decision

EMA/PE/0000223490 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (Vyepti)

Adopted Reference Number: EMADOC-1700519818-1851877